ESR1 and endometrial cancer: ERβ-selective estrogens might be more desirable for HT than ERα-selective estrogens, because studies indicate that ERα mediates cell proliferation that contributes to breast and endometrial cancer whereas ERβ generally is thought to counteract ERα-dependent cell proliferation and tumor formation [21], [22], [23].